Market Place
Sourcing Support
IGC Pharma Announces New IGC-AD1 Alzheimer`s Data
18 Sep 2024 //
BUSINESSWIRE
IGC Pharma Advances IGC-AD1 Toward Trials for Alzheimer`s Anti-Amyloid Treatment
04 Sep 2024 //
BUSINESSWIRE
IGC Announces Results of its 2024 Annual Stockholders Meeting
26 Aug 2024 //
BUSINESSWIRE
IGC Pharma`s IGC-1C Targets Tau Protein In Alzheimer`s
22 Aug 2024 //
BUSINESSWIRE
IGC Pharma Expands Portfolio With Potential GLP-1 Agonist IGC-1A
20 Aug 2024 //
BUSINESSWIRE
IGC Pharma Reports First Quarter Fiscal 2025 Results
08 Aug 2024 //
BUSINESSWIRE
IGC Pharma Gets "Buy" Rating From Alliance Global Partners
18 Jul 2024 //
BUSINESSWIRE
TGR-63 Shows Blood-Brain Barrier Permeability And Safety Profile
09 Jul 2024 //
BUSINESSWIRE
IGC Pharma`s TGR-63 Shows Promise in Reducing Alzheimer`s Amyloid Plaque
25 Jun 2024 //
BUSINESSWIRE
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
25 Jun 2024 //
BUSINESSWIRE
IGC Pharma To Participate In Fireside Chat With Ascendiant Capital Markets
18 Jun 2024 //
BUSINESSWIRE
IGC Pharma Publishes Study In European Society Of Medicine Investigating
10 Jun 2024 //
BUSINESSWIRE
IGC`s announces patient enrollment at Neurostudies in Ph 2 trial investg IGC-AD1
29 May 2024 //
INDIANPHARMAPOST
IGC Pharma: Patient Enrollment In IGC-AD1 Alzheimer`s Phase 2 Trial
28 May 2024 //
BUSINESSWIRE
IGC Pharma to Attend BIO International Convention 2024
21 May 2024 //
BUSINESSWIRE
IGC-AD1 Shows Reduced Alzheimer`s Agitation At Week Two
16 Apr 2024 //
BUSINESSWIRE
IGC Pharma Adds Advisor in Artificial Intelligence
09 Apr 2024 //
BUSINESSWIRE
IGC Pharma Announces $3M Unregistered Private Placement of its Common Stock
26 Mar 2024 //
BUSINESSWIRE
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare 2024
20 Mar 2024 //
BUSINESSWIRE
IGC Announces Positive Results for IGC-AD1 in Reducing Alzheimer’s Agitation
20 Mar 2024 //
BUSINESSWIRE
IGC Pharma Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
12 Mar 2024 //
BUSINESSWIRE
IGC Pharma Announces Equity Analyst Coverage by Ascendiant
23 Feb 2024 //
BUSINESSWIRE
IGC Pharma Reports Third Quarter Fiscal 2024 Results
16 Feb 2024 //
BUSINESSWIRE
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer`s Mouse Model
01 Feb 2024 //
BUSINESSWIRE
IGC Pharma Breakthrough: Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
23 Jan 2024 //
BUSINESSWIRE
IGC Activates ClinCloud, One of 12 Sites in Ongoing Ph 2b Alzheimer’s Trial
17 Jan 2024 //
BUSINESSWIRE
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM
13 Dec 2023 //
BUSINESSWIRE
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
06 Dec 2023 //
BUSINESSWIRE
IGC Pharma Announces Master Agreement with Leading South American University
21 Nov 2023 //
BUSINESSWIRE
IGC Pharma Reports Second Quarter Fiscal 2024 Results
13 Nov 2023 //
BUSINESSWIRE
IGC Pharma Granted European Patent for Groundbreaking Topical Relief Therapy
19 Oct 2023 //
BUSINESSWIRE
IGC Announces Results of its 2023 Annual Stockholders Meeting
21 Aug 2023 //
BUSINESSWIRE
IGC Pharma Expands Phase 2 of IGC-AD1 to Include the University of Puerto Rico
02 Aug 2023 //
BUSINESSWIRE
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1
18 Jul 2023 //
BUSINESSWIRE
IGC Reports Financial Results for Fiscal Year Ended March 31, 2023
12 Jul 2023 //
BUSINESSWIRE
IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts
07 Jul 2023 //
BUSINESSWIRE
IGC Pharma Announces a $3 Million Private Placement of its Common Stock
06 Jul 2023 //
BUSINESSWIRE
IGC Pharma Receives Notice of Allowance for Patent on Seizures
06 Jun 2023 //
BUSINESSWIRE
IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award
05 Jun 2023 //
BUSINESSWIRE
IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023
18 Apr 2023 //
ACCESSWIRE
IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022
14 Feb 2023 //
GLOBENEWSWIRE
IGC to be Featured in Feb. 10 Radius Research Investor Webinar
08 Feb 2023 //
GLOBENEWSWIRE
IGC Announces Updated Life Sciences Presentation
20 Dec 2022 //
GLOBENEWSWIRE
IGC Applauds Signing of Bipartisan Medical Marijuana & Cannabidiol Expansion
07 Dec 2022 //
GLOBENEWSWIRE
IGC to Present at the RHK 2022 Disruptive Growth Conference
30 Nov 2022 //
GLOBENEWSWIRE
IGC Announces Issuance of Second Patent for the Treatment of Alzheimer
21 Sep 2022 //
BUSINESSWIRE
IGC Reports Financial Results for the Quarter Ended June 30, 2022
08 Aug 2022 //
BUSINESS WIRE
IGC Reports Financial Results for Fiscal Year Ended March 31, 2022
22 Jun 2022 //
BUSINESSWIRE
IGC Receives U.S. Patent for Method & Composition for Treating Seizure Disorders
08 Jun 2022 //
BUSINESSWIRE
IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients
07 Sep 2021 //
BIOSPACE
IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimers
22 Jun 2021 //
BUSINESSWIRE
